Oxford’s Corona vaccine can be found in India for just Rs 225
Corona cases in India are increasing very fast now and India has reached the first place in the number of infected people every day. In such a situation, now people are expecting from the trial of corona vaccine. In this case, people have the highest expectations from the Oxford University vaccine, whose human trial is in the final stages. According to the English newspaper Economic Times, a poor and middle class family in India can get this vaccine for just Rs 225.
Among the companies and countries that are at the forefront of developing the corona vaccine in the world are Moderna, Russia and Oxford University. Serum Institute of India, one of the world’s largest vaccine companies, is also a partner in the Corona vaccine being developed at Oxford University.
After the successful trial of the Corona vaccine being developed at Oxford University, the Serum Institute of India will produce it on a large scale in India. The CEO of this company, Adar Poonawala, had said in the past that this vaccine will be sold in India under the name of Kovyshield and it can cost up to one thousand rupees.
However, according to the Economic Times claim, the serum company can sell the Corona vaccine at a rate of just Rs 225 in India. According to ET’s report, the Oxford-AstraZeneca COVID-19 vaccine can be offered to people in low- and middle-income countries for a price of only $ 3, or about Rs 225, after getting the security clearance.
Now you must be thinking how will the company provide the vaccine so cheaply? The answer to this question is the Gates Foundation, which is giving a risk-fund of about $ 150 million to vaccine-producing companies. This money will help the serum company to minimize manufacturing costs.
In a statement, Serum Institute of India CEO Adar Poonawala said, “The widespread spread of the virus has put the whole world in uncertainty. To prevent vaccination and epidemics all over the world, it is important to ensure that the world’s farthest and Access to cheaper treatment and preventive measures is possible in the poorest countries. Through this association, we want to fulfill our continuous efforts to save the lives of millions of people from this terrible disease. “
The Oxford University vaccine has been approved to begin Phase 2 and 3 trials in India last week. Approval is still awaited for testing of Novaxin in India.
